S&P 500 Futures Fall in Premarket Trading; GitLab, Albemarle Lag [MarketWatch]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: MarketWatch
Roivant Sciences Ltd. (ROIV), Baxter International Inc. (BAX), and Leonardo DRS Inc. (DRS) were all posting gains of at least 4%. In early trading, GitLab Inc. Cl A (GTLB) and Albemarle Corp. (ALB) had posted declines, falling 21.8% and 6.6%, respectively. Meanwhile S&P 500 futures were down 0.25%, with futures for the Dow Jones Industrial Average falling 0.15%. The Cboe Volatility Index futures were up 0.21%. Advertisement In commodities news, Brent crude oil futures were down 0.69%, and gold futures were up 0.22%. Bitcoin was down 1.08% to $66,978. The 10-Year Treasury yield slipped to 4.191%. In the previous regular trading session, the S&P 500 and the Dow were down 0.12% and 0.25%, respectively. Stocks in Asia were mixed overnight, with Japan's NIKKEI 225 Index down 0.03% and China's Shanghai Composite Index up 0.28%. In afternoon trading, stocks in Europe are mixed, with the STOXX Europe 600 Index dropping 0.13% and the FTSE 100 Index climbing 0.01% from the previous
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]Seeking Alpha
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- ROIV's page on the SEC website